Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

BACKGROUND: Aberrant progesterone/receptor activator of nuclear factor κβ (RANK) signaling has been implicated in BRCA1 breast cancer development. Furthermore, lower circulating RANKL has been reported among women with a BRCA mutation compared to non-carriers; however, there have been no reports of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zaman, Tasnim, Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497430/
https://ncbi.nlm.nih.gov/pubmed/31069010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26810
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky